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AbstrAct
Objective Exercise intolerance is a clinical hallmark 
of chronic conditions. The present study determined 
pathophysiological mechanisms of exercise intolerance in 
cardiovascular, neuromuscular, and metabolic disorders.
Methods In a prospective cross-sectional observational 
study 152 patients (heart failure reduced ejection 
fraction, n=32; stroke, n=34; mitochondrial disease, 
n=28; type two diabetes, n=28; and healthy controls, 
n=30) performed cardiopulmonary exercise testing with 
metabolic and haemodynamic measurements. Peak 
exercise O
2 consumption and cardiac power output were 
measures of exercise tolerance and cardiac performance.
Results Exercise tolerance was significantly diminished in 
patients compared with controls (ie, by 45% stroke, 39% 
mitochondria disease, and 33% diabetes and heart failure, 
p<0.05). Cardiac performance was only significantly 
reduced in heart failure (due to reduced heart rate, stroke 
volume, and blood pressure) and mitochondrial patients 
(due reduced stroke volume) compared with controls (ie, 
by 53% and 26%, p<0.05). Ability of skeletal muscles 
to extract oxygen (ie, arterial-venous O
2 difference) was 
diminished in mitochondrial, stroke, and diabetes patients 
(by 24%, 22%, and 18%, p<0.05), but increased by 21% 
in heart failure (p<0.05) compared with controls. Cardiac 
output explained 65% and 51% of the variance in peak O
2 
consumption (p<0.01) in heart failure and mitochondrial 
patients, whereas arterial-venous O2 difference explained 
69% (p<0.01) of variance in peak O2 consumption in 
diabetes, and 65% and 48% in stroke and mitochondrial 
patients (p<0.01).
Conclusions Different mechanisms explain exercise 
intolerance in patients with heart failure, mitochondrial 
dysfunction, stroke and diabetes. Their better 
understanding may improve management of patients, their 
stress tolerance and quality of life.
IntroductIon
Exercise intolerance is a clinical hallmark of 
chronic diseases associated with increased 
morbidity and mortality, and reduced quality 
of life for patients.1–7 Healthy individuals with 
diminished exercise tolerance demonstrate 
higher rates of mortality, and increased inci-
dence of heart failure and coronary artery 
disease.1 2 8 Similarly, patients with type two 
diabetes, stroke, heart failure, pulmonary, 
and neuromuscular disorders presented 
with lower level of exercise tolerance show 
increased rate of disease progression and 
mortality.3–7 It is therefore not surprising that 
exercise intolerance has been an important 
therapeutic target in chronic conditions 
using both pharmacological and physiolog-
ical interventions.9–13
Exercise intolerance is a complex clinical 
syndrome represented with reduced oxygen 
(O2) consumption during physiological stim-
ulation.14 Aetiology of exercise intolerance 
can be explained by diminished capacity of 
the cardiovascular system to supply oxygen 
(heart function and cardiac output), and 
inability of the skeletal muscles to utilise 
delivered oxygen (mitochondrial function), 
Key questIons
What is already known about this subject?
 ► Exercise intolerance is a clinical hallmark of 
chronic conditions and strong predictor of 
morbidity and mortality.
What does this study add?
 ► The study highlights that pathophysiological 
mechanisms of exercise intolerance differ among 
patients groups.
How might this impact on clinical practice?
 ► Clinical care teams may improve management 
of patients, their stress tolerance and quality 
of life by prescribing appropriate interventions 
specifically targeting the underlying cause of 
exercise intolerance that is, heart function and / or 
ability of skeletal muscles to extract oxygen.
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or both.14 In healthy individuals exercise capacity seems 
to be limited by the ability of the cardiovascular system 
to deliver oxygen to the exercising muscles.15 In patients 
with chronic conditions, that is,. diabetes mellitus, cardio-
vascular, pulmonary, and neuromuscular disorders, the 
pathophysiology of exercise intolerance is not well under-
stood with evidence supporting mechanisms associated 
with peripheral and/or central (cardiac) limitations to 
exercise.16–22 Although aetiology of exercise intolerance 
in heart failure has been studied more extensively than 
any other chronic condition, the evidence so far has been 
equivocal.23–29
Better understanding of mechanisms of exercise intol-
erance is important as it may lead to improved patient 
management and quality of life. Therefore, the present 
study was designed to determine underlying pathophys-
iological mechanisms of exercise intolerance in patients 
with different chronic conditions. We tested the hypoth-
esis that diminished cardiac performance is the major 
cause of exercise intolerance in cardiovascular, neuro-
muscular, and metabolic disorders.
Methods
study design
Prospective, single-centre, cross-sectional, observational 
study evaluated mechanisms of exercise intolerance in 
patients with cardiovascular, neuromuscular, and meta-
bolic disorders. Data were collected between September 
2012 and January 2016, and analysed between February 
and June 2016. The study was approved by the Research 
Ethics Committee North East of England - Tyne and Wear 
South.
Participants
One hundred and fifty two patients were recruited to 
participate in this study. Study participants included: 1) 
32 patients with stable chronic heart failure with reduced 
left ventricular ejection fraction (LVEF, 32%±9%; New 
York Heart Association functional class II and III), 2) 34 
patients with a history of ischaemic stroke >6 months prior 
to the study (National Institutes of Health Stroke Scale 
average score of 3, ranging from 0 to 8) with no concom-
itant history of heart failure. All stroke patients were 
able to mobilise independently with/without a stick for 
6 min; 3) 28 patients with mitochondrial disease related 
to either the m.3243A >G or m.8344A>G mutation with 
clinical stability for >6 months and no history of coronary 
artery disease or heart failure. Disease burden was mild 
or moderate in all patients (14 patients had MIDD, 12 
had myopathic phenotype and two patients had MELAS). 
4) 28 patients with well-controlled type two diabetes 
for >6 months with no history of coronary artery disease 
or heart failure, and average HbA1c of 7.0%±0.8%; 
and 5) 30 healthy individuals with no history of disease 
or contraindications to exercise testing. Comprehen-
sive screening was completed in all patients including 
a detailed medical history, physical examination, blood 
pressure, ECG, and exercise stress testing. Participants 
were excluded from the study if they had an absolute 
contraindication to cardiopulmonary exercise stress 
testing previously suggested.30 All participants provided 
informed written consent according to the Declaration 
of Helsinki.
Procedures
All participants underwent graded cardiopulmonary 
exercise testing using an electromagnetically controlled 
semi-recumbent bicycle ergometer (Corival; Lode, 
Groningen, The Netherlands) with non-invasive gas-ex-
change (Metalyzer 3B, Cortex, Leipzig, Germany) and 
cardiac output with the bioreactance method (NICOM, 
Cheetah Medical, Delaware).31 32 The signal processing 
unit of the NICOM determines the relative phase shift 
(Δα) between input signals relative to the output signal. 
The Δα is in response to any changes in blood flow that 
pass through the aorta. Cardiac output is then derived 
by Cardiac output=(C×VET×Δα dtmax)×HR, where C is 
the constant of proportionality and VET is ventricular 
ejection fraction time.31 32 The value of C has been previ-
ously validated to account for patient age, gender, height 
and weight. Stroke volume can then be calculated from 
cardiac output and heart rate.
Online expired gas was measured to determine peak O2 
consumption, along with electrocardiography (standard 
12-lead configuration appropriate for exercise testing), 
and non-invasive blood pressure monitoring (brachial 
artery cuff sphygmomanometery). Cardiovascular and 
metabolic measurements were monitored and analysed 
during the 5 min rest period and throughout exercise 
protocol. All participants performed exercise protocol 
until they reached volitional exhaustion, or were unable 
to continue cycling at the required cadence of between 
60–70 revolutions per minute. Peak exercise was defined 
as the absence of any rise in oxygen consumption when 
exercise intensity was increased, inability of the patient to 
continue to pedal at the required cadence, or achieved 
respiratory exchange ratio >1.1. Peak O2 consumption 
was defined as the average oxygen uptake in the last 30 s 
of exercise. Cardiac power output (watts), as the measure 
of overall cardiac function and performance,33 was calcu-
lated using the following equation: CPO = (QT x MAP) x 
2.22×10–3, where QT is cardiac output, MAP is the mean 
arterial pressure, and 2.22×10–3 is the conversion factor.34 
Arteriovenous oxygen difference (a-vO2), was calculated 
as the ratio between O2 consumption and cardiac output, 
represents the ability of the skeletal muscles to extract 
delivered O2.
14
statistical analyses
Statistical analysis was carried out using SPSS version 21 
(SPSS, Inc., Chicago, Illinois). Prior to analysis, all data 
were screened for univariate outliers using Z-distribution 
cut-off scores, and multivariate outliers were detected via 
the Mahalanobis distance test. A Kolmogorov-Smirnov 
test was used to assess the normality of distribution of the 
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data. To test differences in measured variables between 
the patients groups, a one-way analysis of variance was 
used. To identify the groups that differed significantly 
from one another, a post-hoc Tukey’s test was performed. 
The relationship between exercise tolerance and its deter-
minants was assessed using Pearson’s product moment 
coefficient of correlation (r). The meaningfulness of the 
coefficient of correlation was evaluated by calculating the 
coefficient of determination (R.2 Statistical significance 
was indicated if p<0.05. All data are presented as means 
(SD, SD) unless otherwise indicated.
results
Study participants demographic details are presented in 
table 1. Patients with mitochondrial disease had a signifi-
cantly lower age (p<0.01) compared with other groups.
Measurements at rest
The heart failure patients demonstrated significantly 
lower values of cardiac variables including cardiac power 
output, blood pressure, and cardiac output compared 
with other groups (p<0.05; table 2). Resting heart rate was 
highest in mitochondrial disease, which was significantly 
higher than in heart failure and healthy participants 
(27% and 15% respectively, p<0.05). Cardiac power 
output index and stroke volume index were significantly 
lower in heart failure patients compared with healthy 
controls (p<0.05, figure 1A-B). Oxygen consumption was 
similar between the groups, with mitochondrial disease 
only demonstrating higher values than diabetes (p<0.05, 
table 2, figure 1C). Arterial-venous O2 difference was also 
similar between the groups, except heart failure demon-
strating significantly higher values (table 2, figure 1D).
exercise tolerance and its determinants
All participants demonstrated a significant effort during 
cardiopulmonary exercise testing reflected with peak 
exercise respiratory exchange ratio >1.10 (healthy, 
1.16±0.10; diabetes, 1.14±0.11; stroke, 1.10±0.06; mito-
chondria, 1.13±0.09; and heart failure, 1.12±0.08). 
Table 1 Participants’ Demographic and Clinical Characteristics
Healthy
Controls (n=30)
Diabetes
(n=28)
Stroke
(n=34)
Mitochondrial 
Disease (n=28)
Heart
Failure (n=32)
Age, y 55 (12)* 60 (9)† 62 (7)‡ 48 (9)§ 62 (11)
Male, No. (%) 23 (75) 22 (80) 27 (80) 20 (70) 25 (77)
Weight, Kg 76.8 (12.7)¶ 91.1 (12.2)† 83.0 (14.3)‡ 66.1 (14.9) 79.6 (17.3)
Height, Cm 170 (10) 171 (8) 175 (7) 171 (9) 172 (10)
Body Mass Index, kg/m2 27 (4)¶ 31 (5)**,††, † 27 (4) 26 (5)‡ 26.6 (4.0)
Body Surface Area, m2 1.9 (0.1) 2.0 (0.3) 2.0 (0.2) 1.8 (0.1)† 1.9 (0.2)
History of Coronary Artery 
Disease, No. (%)
– – 7 (21) – 15 (48)
History of Hypertension,
No. (%)
– 11 (40) 27 (80) 7 (25) 23 (71)
History of Hyperlipidemia, No. (%) – 17 (60) 19 (55) 10 (36) 17 (47)
History of Diabetes – 28 (100) 11 (33) 15 (55) 8 (24)
Receiving Metformin,
No. (%)
– 20 (70) – 8 (30) 6 (18)
Receiving Insulin, N. (%) – – – – 2 (6)
Receiving ACE or ARB,
No. (%)
– 11 (40) 27 (80) 13 (45) 30 (94)
Receiving β-blocker, No. (%) – – 9 (25) 3 (10) 32 (100)
Calcium channel blocker,
No. (%)
– – 5 (15) 3 (10) 8 (24)
Receiving statin – 17 (60) 19 (55) 11 (36) 30 (94)
Receiving Antiarrhythmic, No. (%) – – 9 (25) 4 (15) 15 (47)
Significant differences between groups (significanc e p<0.05, data ext rapolated from on e-way ANOVA an d Tukey post-hoc test):
*Mitochondrial Disease vs Healthy 
†Mitochondrial Disease vs Diabetes
‡Stroke vs Mitochondrial Disease
§Heart Failure vs Mitochondrial Disease
¶Diabetes vs Healthy
**Heart Failure vs Diabetes
††Stroke vs Diabetes
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker
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Forty-two % stroke patients terminated exercise test 
before reaching respiratory exchange ratio >1.10. 
Similarly, in 22% and 26% of mitochondrial and heart 
failure patients were not able to continue to pedal at the 
required cadence before reaching respiratory exchange 
ratio of >1.10.
Anaerobic threshold, expressed as a percentage of 
achieved peak oxygen consumption, was achieved in 
all patients, and was significantly reduced in patients 
compared with controls (healthy, 62±12; diabetes, 52±13; 
stroke, 46±8; mitochondria, 44±14; and heart failure, 
48±9, p<0.05).
Peak exercise O2 consumption was significantly dimin-
ished in patients compared with controls that is, by 33% 
in diabetes and heart failure, 39% in mitochondrial 
disease, and 45% in stroke (p<0.05, table 2, figure 1C). 
Peak exercise cardiac output was only significantly 
reduced in heart failure and mitochondrial patients 
compared with controls i.e. by 59% and 30% (p<0.05), 
respectively as was cardiac power output by 53% and 
26% (p<0.05, table 2, figure 1A). Cardiac performance 
Table 2 Resting and Peak Exercise Cardiovascular and Metabolic Variables. Data presented as mean (SD).
Healthy
Controls (n=30)
Diabetes
(n=28)
Stroke
(n=34)
Mitochondrial 
Disease (n=28)
Heart
Failure (n=32)
Resting metabolic and cardiac variables
Oxygen consumption, mL/
kg/min
3.9 (0.8) 3.3 (1.0)* 3.6 (0.8) 4.2 (0.8) 4.0 (0.8)
Heart rate, bpm 69 (8)† 76 (10)‡ 74 (10)§ 79 (10)¶ 62 (10)
Mean blood pressure, 
mmHg
101 (10) 106 (11)‡ 102 (11) 108 (16)¶ 92 (9)
Cardiac index, L/min/m2 3.5 (0.6)** 3.1 (0.4)‡ 3.2 (0.5)§ 3.4 (0.4)¶ 2.2 (0.2)
Cardiac power output, Watts 1.41 (0.29)** 1.33 (0.28)‡ 1.39 (0.27)§ 1.48 (0.41) ¶ 0.86 (0.23)
Stroke Volume, mL/beat 95.1 (22.9)**, † 83.0 (15.3) 83.7 (13.9) 77.8 (13.2) 68.4 (17.1)
Peripheral vascular 
resistance, dyne/s/cm2
Ddsd 1215 (252) **, † 1368 (308) 1275 (296) 1416 (351) 1795 (382)
Arteriovenous oxygen 
difference, mL/100 mL
4.7 (0.9)** 5.5 (2.1)‡ 4.9 (1.2)§ 4.6 (1.2) ¶ 7.2 (2.2)
Peak exercise metabolic and cardiac variables
Oxygen consumption, mL/
kg/min
33.1 (12.1)**, ††, †, ‡‡ 21.9 (5.3) 17.7 (4.5) 19.5 (5.4) 22.0 (5.3)
Heart rate, bpm 157 (24)**, * 153 (14)‡, §§ 127 (26)§ 150 (24)¶, ** 117 (25)
Oxygen pulse, mL/beat 16.2 (4.4)**, *, †, †† 13.0 (4.1)‡, * 11.6 (3.9) 8.6 (3.2)¶ 12.2 (4.5)
Mean blood pressure, 
mmHg
130 (11)** 140 (16)‡, * 133 (9)§ 125 (13)¶ 105 (15)
Cardiac index, L/min/m2 9.9 (2.4)**, † 8.6 (1.9)‡ 8.0 (1.2)§ 8.4 (1.6) 6.1 (1.1)
Cardiac power output, Watts 5.41 (1.70)**, † 5.37 (1.11)‡, * 4.71 (1.14)§ 3.98 (1.11) 2.56 (1.53)
Stroke Volume, mL/beat 125.7 (36.9)**, † 126.8 (29.1)§§ 128.9 (30.1) 96.5 (24.7) 102.9 (43.5)
Peripheral vascular 
resistance, dyne/s/cm2
553 (128)** 651 (192) 665 (177) 662 (204) 724 (298)
Arteriovenous oxygen 
difference, mL/100 mL
11.9 (3.0)**, *, † 9.8 (3.8)‡ 9.3 (2.4)§ 9.1 (2.6)¶ 14.4 (4.2)
Ventilatory efficiency slope 27.2 (6.4)**, *, † 29.8 (8.1)‡, *, §§ 32.4 (7.4) 35.7 (8.3) 36.7 (7.8)
Significant differences between the groups (significance p<0.05, data extrapolated from one-way ANOVA and Tukey post-hoc test):
*Mitochondrial Disease vs Diabetes 
†Mitochondrial Disease vs Healthy 
‡Heart Failure vs Diabetes 
§Heart failure vs Stroke 
¶Heart Failure vs Mitochondrial Disease 
**Heart Failure vs Healthy 
††Stroke vs Healthy 
‡‡Diabetes vs Healthy 
§§Stoke vs Diabetes 
¶¶Stoke vs Mitochondrial Disease
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was diminished due to reduced heart rate (25%), stroke 
volume (18%), and mean arterial blood pressure (19%) 
in heart failure (p<0.05), and stroke volume (23%) in 
mitochondrial patients (p<0.05) compared with healthy 
controls. Arterial-venous O2 difference was significantly 
reduced in stroke, mitochondrial, and diabetes patients 
compared with healthy controls that is, by 22%, 24%, and 
18% (p<0.05), but significantly increased in heart failure 
by 21% (p<0.05, table 2, figure 1D).
relationship between exercise tolerance, cardiac 
performance and arterial-venous o2 difference
When data from all study participants were combined, 
there was a significant positive moderate relationship 
between peak exercise O2 consumption and cardiac 
output (r=0.59, p<0.01), cardiac power output (0.52, 
p<0.01), and arterial-venous O2 difference (r=0.50, 
p<0.01). Subgroup analysis revealed that exercise toler-
ance was highly dependent on cardiac performance in 
heart failure, with cardiac output explaining 65% of the 
variance in peak O2 consumption, respectively (r=0.81, 
p<0.01, table 3). Furthermore, ability of skeletal muscles 
to extract O2 was the major determinant of exercise 
tolerance in stroke and diabetes, with arterial-venous 
O2 difference explaining 65% (r=0.81, p<0.01) and 69% 
(r=0.83, p<0.01) of the variance in peak oxygen consump-
tion respectively. In healthy controls and mitochondrial 
patients, exercise tolerance was significantly influenced 
by both, central and peripheral factors such that cardiac 
Figure 1 Central haemodynamic and functional capacity variables measured at rest and peak exercise that is, Cardiac power 
output index (A), Stroke volume index (B), Oxygen consumption (C), Arteriovenous oxygen difference (D) in different patients 
groups.
Table 3 Relationship between peak exercise oxygen consumption and cardiac output and arteriovenous oxygen difference
O2 consumption ~ Cardiac output (L/min)
O2 consumption ~ Arterial-venous O2 different 
(mL)
r R2 p r R2 p
Healthy 0.556 0.309 0.002 0.670 0.449 0.001
Diabetes 0.108 0.011 0.690 0.832 0.692 0.000
Stroke 0.511 0.261 0.021 0.807 0.651 0.000
Mitochondrial 
Disease
0.714 0.509 0.000 0.695 0.483 0.000
Heart Failure 0.808 0.652 0.000 0.160 0.026 0.555
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output explains 31% and 51% (p<0.01), whereas arteri-
al-venous O2 difference 44% and 48% (p<0.01) of the 
overall variance in peak O2 consumption (table 3).
dIscussIon
The main finding of the present study suggests that 
pathophysiological mechanisms underlying exercise 
intolerance differ between the clinical groups. The 
major limitation to exercise in heart failure is diminished 
cardiac performance, whereas in stroke and diabetes 
the major contributor to exercise intolerance is reduced 
ability of skeletal muscles to extract O2. In mitochondrial 
patients exercise tolerance was significantly influenced 
by both, central and peripheral factors. These findings 
may have important clinical implications that is, that 
therapeutic pharmacological and physiological interven-
tions targeting exercise intolerance need to be specific 
and tailored towards clinical presentation of an indi-
vidual patient and in the line with aetiology of functional 
impairment. Results from the present study add novelty 
to the existing literature by providing for the first time 
direct comparison between mechanisms of exercise intol-
erance among patients with different underlying chronic 
conditions. Exercise intolerance in a clinical hallmark of 
many chronic diseases and better understanding of its 
pathology may lead to better patient management and 
clinical outcomes.
As expected exercise tolerance was significantly 
diminished in patients compared with healthy subjects. 
However, peak O2 consumption interestingly was not 
significantly different among the patient groups and 
was in the range of ~10% from each other. Heart failure 
with reduced ejection fraction and diabetes patients 
demonstrated similar level of exercise tolerance which 
is by ~30% lower than in healthy controls. However, the 
mechanisms of exercise intolerance are clearly distinct 
with cardiac performance (ie, peak exercise cardiac 
output and cardiac power output) being reduced in 
heart failure by ~40% and~50% compared with healthy 
controls. This finding is supported by previous inves-
tigations in heart failure due to left ventricular systolic 
dysfunction suggesting that the major determinant of 
exercise tolerance is impaired cardiac function, whereas a 
significant arterial-venous O2 difference reserve suggests 
skeletal muscle per se contributes minimally to limiting 
exercise capacity.27–29
Contrary to heart failure, patients with diabetes demon-
strate cardiac performance which is only ~10% lower 
than healthy controls. This may be a surprising finding 
considering susceptibility of patients with diabetes to 
cardiac dysfunction and heart failure even in the absence 
of coronary artery disease, hypertension, and valvular 
disease.35 36 However, in agreement with our findings, 
previous studies also reported that peripheral mecha-
nisms and skeletal muscles ability to extract delivered O2 
was the main determinant of the O2 uptake during exer-
cise in patients with type two diabetes.16 22 As previously 
suggested type two diabetic skeletal muscle demonstrates 
a transient imbalance of muscle oxygen delivery rela-
tive to oxygen uptake after onset of exercise, suggesting 
a slowed microvascular blood flow increase in type two 
diabetic muscle.16 Impaired vasodilatation due to vascular 
dysfunction in type two diabetes during exercise may 
contribute to this observation.16
Similarly as in diabetes, the major mechanisms of 
exercise intolerance in stroke patients was not cardiac 
performance but rather significantly reduced ability 
of skeletal muscles to extract O2, explaining remark-
able ~65% of the variance in measured O2 consumption. 
A limited number of studies have reported pathophys-
iology of exercise intolerance in stroke. While it was 
initially argued that cardiac performance that is, cardiac 
output to be reduced by ~1/3 in stroke patients,18 later 
study reported that cardiac function response to exercise 
is preserved,17 confirming the finding of the present study 
that exercise capacity is predominantly effected by skel-
etal muscle dysfunction. People who suffer from stroke 
are often left with residual physical impairments limiting 
physical function. Unique structural and metabolic 
abnormalities have been demonstrated in hemiparetic 
muscle post-stroke which may be a direct result of stroke 
or caused by an indirect reduction in physical activity 
levels due to impairment further exacerbating reduction 
in skeletal muscle mass.37 The neurological involvement 
of the individual may also play a key role in determining 
exercise intolerance, for example, spasticity of the lower 
extremities, or poor motor coordination.5
Mitochondrial disease patients, despite being the 
youngest group, demonstrated functional capacity 
that was ~12% lower than that of heart failure. When 
compared with healthy controls, mitochondrial patients 
showed significantly diminished both, cardiac and 
peripheral muscle performance by ~25%, with the lowest 
arterial-venous O2 difference among the patient groups. 
It is interesting to note that, in contrast with other clin-
ical groups, reduced exercise tolerance in patients with 
mitochondrial disease was equally affected by both, 
central and peripheral factors with cardiac output and 
arterial-venous O2 difference explaining 31% and 51% of 
the variance in O2 consumption. Mitochondrial disease 
patients do not seem to have the compensatory mecha-
nism seen in heart failure, possibly due to an increased 
defective mitochondrial content in the muscle and oxida-
tive phosphorylation, preventing efficient oxygen uptake 
into the working muscles.38 Mitochondrial patients 
attempted to overcome defective arterial-venous O2 
difference by increasing the heart rate to support peak 
oxygen consumption. However, overall cardiac reserve 
(difference between peak exercise and resting heart 
rate) was diminished because resting heart rate was 
increased. Additionally, reduced chronotropic compe-
tence is featured with reduced ability to increase stroke 
volume. Our findings are supported by previous studies 
which also highlighted the inability of mitochondrial 
disease patients to exceed 10 mL arterial-venous O2 
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difference due to impaired respiratory chain function, 
reducing the capacity of the skeletal muscles to extract 
delivered oxygen.39 This confirms the complex nature of 
this systemic disorder effecting both the heart and skel-
etal muscle.19
In the present study the following limitations should 
be considered. First, the overall sample size in each of 
the group was moderate and non-invasive bioreactance 
method was used to assess central haemodynamics. 
Second, the mean age of the mitochondrial patients was 
significantly less than the other groups. Results reveal 
however that most of the physiological variables were 
in fact lower than reported in other groups despite the 
younger age, and in the line with clinical presentation 
of mitochondrial disease patients. Thirdly, the disease 
associated concomitant medication was different among 
the groups, and particularly the use of beta-adrenergic 
receptor blockers which has known effect to reduce cardiac 
performance. Patients were however instructed not to 
withdraw medication prior assessment. Lastly, the study 
was not designed to evaluate other factors (in addition 
to cardiac output and arterial-venous oxygen difference) 
that may contribute to impaired oxygen consumption 
during exercise (including muscle biochemistry, micro-
circulation, pulmonary discussion capacity, and oxygen 
carrying capacity), as previously suggested.14 15
conclusIon
The present study suggest that pathophysiology of exer-
cise intolerance differ among patients group. Diminished 
cardiac performance plays dominant role in exercise 
tolerance in patients with heart failure with reduced ejec-
tion fraction, whereas arterial-venous O2 difference is the 
major contributor in patients with diabetes and stroke. 
Exercise capacity in patients with mitochondrial disorders 
is equally affected by both central haemodynamic and 
peripheral factors. These findings may have important 
clinical implications because better understanding of 
the pathophysiology of exercise intolerance in chronic 
diseases may improve management of the patients, their 
stress tolerance and quality of life.
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